Risk of Ischemic Thromboembolism in AF Patients with One Additional Risk Factor of CHA₂DS₂-VASc Score^*.

<p>Risk of Ischemic Thromboembolism in AF Patients with One Additional Risk Factor of CHA₂DS₂-VASc Score^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0151485#t004fn001" target="_blank">*</a>}.</p

Flow Chart of Study Cohort Enrollment.

<p>Patients who received treatments with warfarin or any antiplatelet agent, including aspirin and clopidogrel, were excluded from the study population. A total of 190,210 patients were finally enrolled in the study cohort with 17,595 males with CHA₂DS₂-VASc score of 1 and 9,926 females with CHA₂DS₂-VASc score of 2. Among the 17,595 male patients, there were 3,092, 9,469, and 5,034 patients in the age groups of 20 to 49, 50 to 64, and 65 to 74 years of age, respectively. Among the 9,926 female patients, there were 1,290, 5,983, and 2,653 patients in the age groups of 20 to 49, 50 to 64, and 65 to 74 years of age, respectively. There were other 10,435 males with CHA₂DS₂-VASc score of 0 and 5,984 females with CHA₂DS₂-VASc score of 1 used as the reference group, respectively. AF = atrial fibrillation; CHA₂DS₂-VASc = heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female.</p

Kaplan-Meier Survival Curves in AF patients with One Additional Risk Factor of CHA₂DS₂-VASc Score.

<p><b>A.</b> Cumulative survival curves in male patients with CHA₂DS₂-VASc Score of 1 in the age groups of 20 to 49, 50 to 64, and 65 to 74 years of age, respectively. There is no difference of the cumulative risk of ischemic thromboembolism between male AF patients with CHA₂DS₂-VASc score of 1 for 20 to 49 years of age and overall patients with CHA₂DS₂-VASc score of 0. <b>B.</b> Cumulative survival curves in female patients with CHA₂DS₂-VASc Score of 2 in the age groups of 20 to 49, 50 to 64, and 65 to 74 years of age, respectively. Young female patient with CHA₂DS₂-VASc score of 2 and 20 to 49 years of age showed significantly higher cumulative risk of clincial event as compared with overall female patients with CHA₂DS₂-VASc score of 1.</p

AnnuaI Risk of Ischemic Thromboembolism Stratified by CHA₂DS₂-VASc Score, Gender, and Age among AF patients without anticoagulants.

<p>AnnuaI Risk of Ischemic Thromboembolism Stratified by CHA₂DS₂-VASc Score, Gender, and Age among AF patients without anticoagulants.</p

Baseline Characteristics for AF Patients with One Additional Risk Factor of CHA₂DS₂-VASc Score^*.

<p>Baseline Characteristics for AF Patients with One Additional Risk Factor of CHA₂DS₂-VASc Score^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0151485#t003fn001" target="_blank">*</a>}.</p

MOESM1 of Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Additional file 1: Table S1. International Classification of Disease (9th edition) Clinical Modification (ICD 9-CM) codes used to define the co-morbidities and clinical outcome in the study cohort

MOESM1 of Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Additional file 1: Table S1. International Classification of Disease (9th edition) Clinical Modification (ICD 9-CM) codes used to define the co-morbidities and clinical outcome in the study cohort

MOESM2 of Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Additional file 2: Figure S1. Cumulative risk curve of the new-onset AF for the study cohorts treated with metformin plus DDP-4 inhibitor or other hypoglycemic agents before propensity score weighting. DDP4i group (solid line) had a significantly lower cumulative risk of new-onset AF compared with non-DDP4i group in patients treated with metformin (dotted line). DPP4i dipeptidyl peptidase-4 inhibitor

MOESM1 of A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

Additional file 1. The drugs analyzed are listed as following